- Home
- IRON vs TVTX Comparison
IRON vs TVTX Comparison
Compare IRON & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- TVTX
- Stock Information
- Founded
- IRON 2017
- TVTX 2008
- Country
- IRON United States
- TVTX United States
- Employees
- IRON N/A
- TVTX N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- IRON Health Care
- TVTX Health Care
- Exchange
- IRON Nasdaq
- TVTX Nasdaq
- Market Cap
- IRON 1.4B
- TVTX 1.3B
- IPO Year
- IRON N/A
- TVTX N/A
- Fundamental
- Price
- IRON $59.46
- TVTX $17.72
- Analyst Decision
- IRON Strong Buy
- TVTX Buy
- Analyst Count
- IRON 10
- TVTX 13
- Target Price
- IRON $72.00
- TVTX $23.46
- AVG Volume (30 Days)
- IRON 431.6K
- TVTX 1.4M
- Earning Date
- IRON 11-12-2024
- TVTX 10-31-2024
- Dividend Yield
- IRON N/A
- TVTX N/A
- EPS Growth
- IRON N/A
- TVTX N/A
- EPS
- IRON N/A
- TVTX N/A
- Revenue
- IRON N/A
- TVTX $203,447,000.00
- Revenue This Year
- IRON N/A
- TVTX $62.45
- Revenue Next Year
- IRON N/A
- TVTX $59.30
- P/E Ratio
- IRON N/A
- TVTX N/A
- Revenue Growth
- IRON N/A
- TVTX 57.08
- 52 Week Low
- IRON $25.60
- TVTX $5.12
- 52 Week High
- IRON $77.60
- TVTX $20.33
- Technical
- Relative Strength Index (RSI)
- IRON 58.39
- TVTX 51.53
- Support Level
- IRON $63.21
- TVTX $16.89
- Resistance Level
- IRON $68.73
- TVTX $19.51
- Average True Range (ATR)
- IRON 3.49
- TVTX 1.23
- MACD
- IRON 0.52
- TVTX -0.16
- Stochastic Oscillator
- IRON 61.25
- TVTX 26.69
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.